Press releases

Oncopeptides AB (publ) a biotech company focused on the commercialization, research and development of therapies for difficult-to-treat hematological diseases, will publish the report for the fourth quarter and the 2022 year-end report, at 08:00 (CET) on February 16, 2023

STOCKHOLM - January 18, 2023 - Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on commercialization, research, and development of therapies for difficult-to-treat hematological diseases, today announces that Holger Lembrer, who recently was appointed Chief Financial Officer, CFO, takes the office on January 18

STOCKHOLM — January 11, 2023 — Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Company has appointed Holger Lembrer as Chief Financial Officer, CFO. Prior to joining Oncopeptides Holger Lembrer was Business Unit CFO at Assa Abloy, and before that Investor Relations Officer, and Financial Controller. He has also been a Senior Auditor at Ernst & Young. Holger Lembrer will assume his new position before the end of February 2023 and will replace Annika Muskantor who has been interim CFO since November 1, 2021

STOCKHOLM — January 4, 2023 — Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Board of Directors has appointed Dr Monica Shaw as Chief Executive Officer, CEO, of Oncopeptides. She replaces Jakob Lindberg, who has been the CEO since November 15, 2021. Lindberg assumes his previous position as Chief Scientific Officer. These changes are effective immediately

STOCKHOLM — December 22, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO). According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the annual general meeting 2023 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of September 30 who are willing to participate in the Nomination Committee, along with the Chairman of the Board of Directors

STOCKHOLM — December 12, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the company presents new scientific data including one clinical abstract and three preclinical research posters at the Annual American Society of Hematology Meeting, ASH, in New Orleans, Louisiana, USA, on December 10-13. The clinical abstract evaluated patients with multiple myeloma who were refractory to prior alkylators in the phase 3 OCEAN study. Data shows that melflufen is a safe and effective therapy in patients who are alkylator refractory, regardless of whether they received a prior autologous stem cell transplant or not

STOCKHOLM — December 07, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that the US Food and Drug Administration, FDA, has requested a withdrawal of the US marketing authorization for Pepaxto[® ](melphalan flufenamide, also called melflufen). The request is based on the outcome of the confirmatory phase 3 OCEAN study, which demonstrated an ITT overall survival HR of 1.1, but with significant survival result differences for both melflufen and the comparator drug pomalidomide for large relevant patient groups

STOCKHOLM — November 25, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announced that the company has entered into a renewed unsecured loan facility agreement with the European Investment Bank (EIB), granting access to a conditional loan facility of up to €30 million

STOCKHOLM — November 11, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that Pepaxti[®] (melphalan flufenamide, also called melflufen) has been granted marketing authorization in combination with dexamethasone, by the Medicines & Healthcare products Regulatory Agency, MHRA, in UK

STOCKHOLM — November 9, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today publishes the report for the third quarter 2022